 |
市場調查報告書
商品編碼
1465575
大分子生物分析技術市場規模 - 按產品、技術、應用、最終用途和預測，2024 年 - 2032 年Large Molecule Bioanalytical Technologies Market Size - By Offering, Technology, Application, End-use & Forecast, 2024 - 2032 |
||||||
2024年至2032年，全球大分子生物分析技術市場的複合年成長率將達到10.4%。持續的技術進步提高了大分子分析的靈敏度和效率，滿足生物製劑特性的複雜需求。增加研發投資、不斷擴大的生物製品領域和持續創新的協同作用將推動市場發展，為全球製藥、生物技術和研究領域提供關鍵解決方案。
例如，2024 年 1 月，安捷倫科技推出了 Agilent ProteoAnalyzer 系統，這是一個自動化 CE 平台。它簡化並增強了複雜蛋白質混合物的分析，這對於製藥、生物技術、食品分析和學術界等各個領域至關重要，從而最佳化了這些行業的分析工作流程。
大分子生物分析技術產業根據產品、技術、應用、最終用途和地區進行細分。
由於 CRO 的專業知識、先進技術以及開發和分析複雜生物製劑的簡化流程，到 2032 年，合約研究組織部門將佔據相當大的行業佔有率。隨著製藥和生物技術公司擴大外包其研發活動，CRO 成為關鍵合作夥伴，提供具有成本效益的解決方案並加快時間表。他們提供從臨床前開發到臨床試驗的全面服務，使他們成為推動大分子生物分析領域創新和效率的關鍵參與者。
在這些革命性療法的開發和採用激增的推動下，細胞和基因治療領域的大分子生物分析技術市場將在 2032 年累積可觀的效益。細胞和基因療法需要複雜的生物分析工具來進行精確表徵和監測，從而推動了對專業技術的需求。隨著個人化醫療和生物技術的進步，細胞和基因治療領域將經歷大幅成長，鞏固其作為大分子生物分析技術市場關鍵參與者的地位。
歐洲大分子生物分析技術產業規模從 2024 年到 2032 年將呈現驚人的複合年成長率，這得益於該地區強勁的製藥和生物技術產業，培育了創新和研究文化。歐洲國家擁有許多專門從事大分子分析的生物製藥公司和學術機構。此外，嚴格的監管框架和對尖端技術的投資也增強了歐洲在該市場的地位。歐洲致力於推動生物分析技術，將成為市場擴張的重要貢獻者。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 對生物製劑和生物相似藥的需求不斷增加
- 生物分析技術不斷進步
- 慢性病盛行率增加
- 加強組學領域的研究與開發
- 產業陷阱與挑戰
- 與這些技術相關的高成本
- 缺乏標準化和驗證
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 競爭定位矩陣
- 戰略展望矩陣
第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年
- 主要趨勢
- 產品
- 耗材及配件
- 儀器
- 試劑和試劑盒
- 服務
第 6 章：市場估計與預測：按技術分類，2018 年 - 2032 年
- 主要趨勢
- 色譜法
- 質譜
- 酵素連結免疫吸附試驗
- 電泳
- 聚合酶鍊式反應
- 蛋白質印跡
- 流式細胞儀
- 光譜儀
- 其他技術
第 7 章：市場估計與預測：按應用分類，2018 年 - 2032 年
- 主要趨勢
- 生物製劑
- 寡核苷酸衍生藥物和分子
- 病毒載體
- 細胞與基因治療
- 奈米粒子和聚合物
- 疾病診斷
- 其他應用
第 8 章：市場估計與預測：按最終用途，2018 - 2032 年
- 主要趨勢
- 製藥和生物技術公司
- 合約研究組織
- 研究與學術機構
- 其他最終用戶
第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Cergentis B.V.
- Charles River Laboratories International, Inc.
- Danaher Corporation
- Halo Labs, Inc
- Intertek Group plc
- Laboratory Corporation of America Holdings
- Shizmandu Corporation
- SOLVIAS AG
Global Large Molecule Bioanalytical Technologies Market will record a 10.4% CAGR from 2024 to 2032. Rising R&D expenditure, particularly in biologics development, fuels the demand for advanced analytical tools. Ongoing technological advancements enhance the sensitivity and efficiency of large molecule analysis, catering to the complex needs of biologics characterization. This synergy of increased R&D investment, an expanding biologics landscape, and continuous innovation will propel the market, providing critical solutions for the pharmaceutical, biotech, and research sectors globally.
For instance, in January 2024, Agilent Technologies introduced the Agilent ProteoAnalyzer system, an automated CE platform. It streamlines and enhances the analysis of intricate protein mixtures, crucial in various sectors such as pharmaceuticals, biotech, food analysis, and academia, optimizing analytical workflows for these industries.
The large molecule bioanalytical technologies industry is segmented based on offering, technology, application, end use, and region.
The contract research organization segment will capture a considerable industry share by 2032 due to CROs' specialized expertise, advanced technologies, and streamlined processes for developing and analyzing complex biologics. As pharmaceutical and biotech companies increasingly outsource their research and development activities, CROs emerge as pivotal partners, offering cost-effective solutions and accelerated timelines. Their comprehensive services, spanning from preclinical development to clinical trials, position them as key players driving innovation and efficiency in the large molecule bioanalytical landscape.
The large molecule bioanalytical technologies market from the cell and gene therapy segment will accumulate substantial gains by 2032, fueled by the surge in the development and adoption of these revolutionary therapies. Cell and gene therapies necessitate intricate bioanalytical tools for precise characterization and monitoring, driving the demand for specialized technologies. With a focus on personalized medicine and advancements in biotechnology, the cell and gene therapy segment will experience substantial growth, solidifying its position as a key player in the large molecule bioanalytical technologies market.
Europe large molecule bioanalytical technologies industry size will exhibit a remarkable CAGR from 2024 to 2032, attributed to the region's robust pharmaceutical and biotechnology sectors, fostering a culture of innovation and research. European countries house numerous biopharmaceutical companies and academic institutions specializing in large molecule analysis. Additionally, stringent regulatory frameworks and investments in cutting-edge technologies bolster Europe's position in this market. With a commitment to advancing bioanalytical techniques, Europe will emerge as a substantial contributor to the market expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Public sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing demand for biologics & biosimilars
- 3.2.1.2 Rising advancements in bioanalytical technology
- 3.2.1.3 Increasing prevalence of chronic diseases
- 3.2.1.4 Increasing research and development in the omics sector
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High costs associated with these technologies
- 3.2.2.2 Lack of standardization and validation
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Offering, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Products
- 5.2.1 Consumables & accessories
- 5.2.2 Instruments
- 5.2.3 Reagents & kits
- 5.3 Service
Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Chromatography
- 6.3 Mass spectrometry
- 6.4 ELISA
- 6.5 Electrophoresis
- 6.6 Polymerase chain reaction
- 6.7 Western blot
- 6.8 Flow cytometry
- 6.9 Spectrometer
- 6.10 Other technologies
Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Biologics
- 7.3 Oligonucleotide derived drugs & molecules
- 7.4 Viral vector
- 7.5 Cell & gene therapy
- 7.6 Nanoparticles & polymers
- 7.7 Disease diagnosis
- 7.8 Other applications
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Pharmaceutical & biotechnology companies
- 8.3 Contract research organizations
- 8.4 Research & academic institutes
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Bio-Rad Laboratories, Inc.
- 10.2 Bio-Techne Corporation
- 10.3 Cergentis B.V.
- 10.4 Charles River Laboratories International, Inc.
- 10.5 Danaher Corporation
- 10.6 Halo Labs, Inc
- 10.7 Intertek Group plc
- 10.8 Laboratory Corporation of America Holdings
- 10.9 Shizmandu Corporation
- 10.10 SOLVIAS AG
